Strides Pharma Science Ltd's Chestnut Ridge facility received four procedural FDA observations, with no impact on supply.

Strides Pharma Science Ltd ( ($IN:STAR) ) has issued an update. Strides Pharma Science Limited has announced that its trading window for dealing ...

Bengaluru: Strides Pharma Science has announced that the U.S. Food and Drug Administration (USFDA) has concluded inspection ...

Strides Pharma Science slipped 1.02% to Rs 928.85 after its step-down subsidiary, Strides Pharma Inc. USA (SPI), has received four observations from the USFDA following a routine inspection of its ...

The average one-year price target for Strides Pharma Science (NSE:STAR) has been revised to 565.76 / share. This is an increase of 13.66% from the prior estimate of 497.76 dated August 31, 2023. The ...

The average one-year price target for Strides Pharma Science (NSEI:STAR) has been revised to ₹ 1,244.40 / share. This is a decrease of 19.21% from the prior estimate of ₹ 1,540.20 dated September 27, ...

Partnership strengthens Strides' pipeline of nasal spray products across diverse therapeutic areas Kenox to provide formulation and development expertise in Orally Inhaled and Nasal Drug Products ...

Strides Pharma Science Ltd (BOM:532531) reported a strong quarterly performance with a 4.6% year-on-year revenue growth. The company achieved a significant improvement in gross margins, increasing by ...

BENGALURU (Reuters) - A U.S. Food and Drug Administration (FDA) investigator discovered that India's Strides Pharma Science Ltd, which exports to the U.S. market, was shredding drug production, ...

About Strides Pharma Science Ltd. Strides Pharma Science Ltd. engages in the development, manufacture and distribution of Internet Protocol-led generics and bio-pharmaceutical products. It operates ...

STRIDES PHARMA SCIENCE LTD - Completion Of US-FDA Inspection At The Formulations Facility Of Strides Pharma Inc., USA, A Step-Down Wholly Owned Subsidiary Of The Company - Rediff MoneyWiz, the ...

India's OneSource eyes weight-loss drug boost to order book Indian contract drug manufacturer OneSource Specialty Pharma expects strong growth in its order book over the next three years, driven by ...